Display options
Cite
Ahmadian N, Pashaei-Asl R, Samadi N, et al. Hesa-A Effects on Cell Cycle Signaling in Esophageal Carcinoma Cell Line. Middle East J Dig Dis. 2016;8(4):297-302doi: 10.15171/mejdd.2016.39.
Ahmadian, N., Pashaei-Asl, R., Samadi, N., Rahmati-Yamchi, M., Rashidi, M. R., Ahmadian, M., Esmaeili, M., Salamat, F., Besharat, S., & Joshaghani, H. R. (2016). Hesa-A Effects on Cell Cycle Signaling in Esophageal Carcinoma Cell Line. Middle East journal of digestive diseases, 8(4), 297-302. https://doi.org/10.15171/mejdd.2016.39
Ahmadian, Nasser, et al. "Hesa-A Effects on Cell Cycle Signaling in Esophageal Carcinoma Cell Line." Middle East journal of digestive diseases vol. 8,4 (2016): 297-302. doi: https://doi.org/10.15171/mejdd.2016.39
Ahmadian N, Pashaei-Asl R, Samadi N, Rahmati-Yamchi M, Rashidi MR, Ahmadian M, Esmaeili M, Salamat F, Besharat S, Joshaghani HR. Hesa-A Effects on Cell Cycle Signaling in Esophageal Carcinoma Cell Line. Middle East J Dig Dis. 2016 Oct;8(4):297-302. doi: 10.15171/mejdd.2016.39. PMID: 27957293; PMCID: PMC5145297.
Copy Download .nbib Format: NLM
Share it on

Middle East J Dig Dis. 2016 Oct;8(4):297-302. doi: 10.15171/mejdd.2016.39.

Hesa-A Effects on Cell Cycle Signaling in Esophageal Carcinoma Cell Line.

Middle East journal of digestive diseases

Nasser Ahmadian, Roghiyeh Pashaei-Asl, Nasser Samadi, Mohammad Rahmati-Yamchi, Mohammad-Reza Rashidi, Masomeh Ahmadian, Moosa Esmaeili, Faezeh Salamat, Sima Besharat, Hamid Reza Joshaghani

Affiliations

  1. Faculty of Advanced Medical Science Technology, Golestan University of Medical Sciences, Gorgan, Iran.
  2. Faculty of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  3. Department of Biochemistry, Tabriz University of Medical Sciences, Tabriz, Iran.
  4. Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  5. Women's Reproductive Health Research Center, Alzahra Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
  6. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.

PMID: 27957293 PMCID: PMC5145297 DOI: 10.15171/mejdd.2016.39

Abstract

BACKGROUND Hesa-A is a natural compound with anticancer properties. The exact mechanism of its action in esophageal cancer is not clear, yet. The aim of this study was to evaluate the cell toxicity effect of Hesa-A on the esophageal carcinoma cell lines, KYSE-30, and cell cycle genes expression. METHODS In this study, we tested cell toxicity with MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay and flow cytometry to evaluatet he cell cycle arrest. Real time polymerase chain reaction was used to assess the expression of P53, P16, P21, cyclin D1, and cyclin B1 genes. RESULTS Our results showed that Hesa-A is effective in the expression of cell cycling check point proteins. Hesa-A induced an arrest in G2 phase of esophageal cell cycle. The levels of P53 (>13 times), P21 (>21 times), P16, cyclin B1, and cyclin D1 genes were increased 48 hours after Hesa-A treatment. CONCLUSION P21 and P16 expression were the potential mechanisms for G2 arrest of KYSE-30 esophageal cancer cell line by Hesa-A.

Keywords: Cyclin B1 gene.; Cyclin D1 gene; Esophageal cancer; Flow cytometry; Hesa-A; P16gene; P21 gene; P53 gene; Real Time PCR

References

  1. Genes Dev. 1994 Jul 15;8(14):1627-39 - PubMed
  2. Vet Pathol. 2002 Jul;39(4):458-72 - PubMed
  3. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2147-52 - PubMed
  4. Chin J Integr Med. 2010 Aug;16(4):366-7 - PubMed
  5. Med Sci Monit. 2005 Jun;11(6):CR300-303 - PubMed
  6. Cancer Res. 1994 Mar 1;54(5):1169-74 - PubMed
  7. Mol Cancer Ther. 2002 Jun;1(8):639-49 - PubMed
  8. Cell. 1994 Nov 18;79(4):573-82 - PubMed
  9. Asian Pac J Cancer Prev. 2015;16(16):6963-6 - PubMed
  10. J Dent Res Dent Clin Dent Prospects. 2013 Fall;7(4):218-24 - PubMed
  11. Nature. 1993 Dec 16;366(6456):701-4 - PubMed
  12. Oncol Lett. 2013 Mar;5(3):903-910 - PubMed
  13. Iran J Med Sci. 2012 Mar;37(1):47-53 - PubMed
  14. Cell. 1994 Nov 18;79(4):563-71 - PubMed
  15. Exp Oncol. 2006 Mar;28(1):44-8 - PubMed
  16. Nature. 1993 Apr 29;362(6423):786-7 - PubMed
  17. PLoS One. 2011;6(12):e29488 - PubMed
  18. Clin Cancer Res. 2003 Apr;9(4):1557-65 - PubMed
  19. Asian Pac J Cancer Prev. 2012;13(9):4751-6 - PubMed
  20. Cell Mol Life Sci. 1999 Jan;55(1):28-37 - PubMed
  21. Anticancer Res. 2000 Jan-Feb;20(1A):345-9 - PubMed
  22. Drugs Exp Clin Res. 2005;31(1):1-6 - PubMed

Publication Types